Rep. Waxman leak unlikely to suppress off-label guidance

Share this article:

The chairman of the House Committee on Oversight and Government Reform provoked industry exponents last month by leaking FDA draft guidance on off-label journal reprints. But while his move—on the eve of an election year, no less—riled some, it's unlikely to forestall the guidance or prompt major changes, sources said.

Rep. Henry Waxman (D-CA) had set a Dec. 21 deadline for the FDA to respond to his concerns, asking it to delay issuance until then. At press time, an FDA spokesperson told MM&M the agency “will be responding to the congressman directly.”

The situation is likely to lead to some enforceable rules, said John Kamp, executive director, Coalition for Healthcare Communication. “With the passing of the [FDA Modernization Act] rules, which enabled some off-label distribution of peer-reviewed articles, it's really incumbent on the FDA to bring some clarity to this situation,” Kamp said.

That's not to say Rep. Waxman's criticisms won't be taken into account. The draft criteria would allow drug reps to hand out “truthful and non-misleading” journal reprints and other publications on unapproved uses of approved drugs and devices to healthcare professionals, as long as they are published by a peer-reviewed organization. The congressman is worried about the enforceability of the criteria and that manufacturers will use the guidance as a pretext to promote off-label.

Rep. Waxman's position on the House Committee on Energy and Commerce, which holds sway over FDA, makes him a force to be reckoned with. But the FDA is enjoined from attempting to suppress reprints, said Richard Samp, chief counsel, Washington Legal Foundation, which won a permanent injunction to that effect in 1998.

“Any effort by FDA to adopt a more stringent rule would place it in contempt of court,” Samp said. “Rep. Waxman is entitled to ask the government to take actions in contempt of court; but I don't think that's a particularly responsible suggestion on his part.” 
Share this article:
close

Next Article in News

Email Newsletters

More in News

BMS Q2 sales slip, Eliquis, Yervoy soar

BMS Q2 sales slip, Eliquis, Yervoy soar

The company attributed part of the Eliquis boost to the BMS-Pfizer DTC and education efforts.

Gilead, Merck HCV marketing battle may be on horizon

Gilead, Merck HCV marketing battle may be on ...

Disclosed in its earnings report yesterday, Gilead may have a card up its sleeve to counter Merck's experimental hep. C combo regimen.

Sales of Biogen MS pill pick up overseas

Sales of Biogen MS pill pick up overseas

Biogen Idec is seeing strong sales for blockbuster MS drug Tecfidera, especially overseas where it's beginning to catch fire this summer.